✦ LIBER ✦

Clozapine in tardive dyskinesia

✍ Scribed by George M. Simpson; J. Hillary Lee; Ram K. Shrivastava

Publisher: Springer
Year: 1978
Tongue: English
Weight: 468 KB
Volume: 56
Category: Article
ISSN: 0033-3158
DOI: 10.1007/bf00571412

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Clozapine pharmacology and tardive dyski

Clozapine pharmacology and tardive dyskinesia

✍ Jeffrey Lieberman; Celeste Johns; Thomas Cooper; Simcha Pollack; John Kane 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 688 KB

Clozapine efficacy in tardive dyskinesia

Clozapine efficacy in tardive dyskinesia in schizophrenic patients

✍ D.P. Bassitt; Mário Rodrigues Louzã Neto 📂 Article 📅 1998 🏛 Springer-Verlag 🌐 English ⚖ 59 KB

Clozapine: neuroleptic-induced EPS and t

Clozapine: neuroleptic-induced EPS and tardive dyskinesia

✍ Daniel E. Casey 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 863 KB

Clozapine has had a uniquely favorable motor system side effect profile since its initial evaluations. This has been convincingly corroborated by many double blind, single blind, and open studies treating acute and chronic psychosis. The acute extrapyramidal syndromes of dystonia, akathisia and park

Bereitschaftspotential in tardive dyskin

Bereitschaftspotential in tardive dyskinesia

✍ Dr. Lawrence E. Adler; Mark Pecevich; Herbert Nagamoto 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 518 KB

The bereitschaftspotential or motor readiness potential is a slow negative electroencephalographic wave occurring 150-1500 ms prior to the onset of a voluntary movement. It was measured in 33 subjects: 11 normal controls, 11 medicated schizophrenics with no tardive dyskinesia or evidence of drug-ind

Naloxone in tardive dyskinesia

✍ I. Blum; P. F. Nisipeanu; E. Roberts 📂 Article 📅 1987 🏛 Springer 🌐 English ⚖ 90 KB

Sulpiride in tardive dyskinesia

✍ Daniel E. Casey; Jes Gerlach; Hans Simmelsgaard 📂 Article 📅 1979 🏛 Springer 🌐 English ⚖ 407 KB

Tardive dyskinesia can be suppressed by drugs that block dopaminergic receptors, but often at the cost of a concomitant increase in parkinsonism. Sulpiride (400 -- 2100 mg/day), a selective type-2 dopamine receptor antagonist, was evaluated in a blind, placebo-controlled trial in 11 patients with ta